76.46 F
New York
July 26, 2021

Biogens

Biogen’s controversial Alzheimer’s drug generates $2 million in first few weeks after approval

CNBC
CNBC – For more and to sign up click here Aduhelm by Biogen Source: Biogen Biogen‘s Alzheimer’s drug, Adhulem, generated $2 million in revenue in the first few weeks of its approval, the company said Thursday in releasing its second-quarter earnings along with an open letter about the controversial drug.......

Patient receives first infusion of Biogen’s controversial Alzheimer’s drug

CNBC
CNBC – For more and to sign up click here The exterior of the headquarters of biotechnology company Biogen in Cambridge, MA is pictured on March 21, 2019. John Tlumacki | Boston Globe | Getty Images A 70-year-old man from Rhode Island on Wednesday was the first to receive an......

Third member of prestigious FDA panel resigns over approval of Biogen’s Alzheimer’s drug

CNBC
CNBC – For more and to sign up click here A sign for the Food and Drug Administration is seen outside of the headquarters on July 20, 2020 in White Oak, Maryland. Sarah Silbiger | Getty Images A third member of a key Food and Drug Administration advisory panel has......

Biogen’s Alzheimer’s drug could cost Medicare billions of dollars a year, report finds

CNBC
CNBC – For more and to sign up click here A pedestrian walks past Biogen Inc. headquarters in Cambridge, Massachusetts, on Monday, June 7, 2021. Adam Glanzman | Bloomberg | Getty Images Biogen‘s pricy new Alzheimer’s drug, Aduhelm, could cost Medicare billions of dollars a year, according to an analysis......

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Click whichever is suitable. Accept Read More